echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer announces voluntary recall of all batches of smoking cessation drug varenicline in the U.S.

    Pfizer announces voluntary recall of all batches of smoking cessation drug varenicline in the U.S.

    • Last Update: 2021-11-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Shi Bei

    On September 16, Pfizer announced the recall of all batches of Chantix (Chinese trade name: Changpei, generic name: varenicline, varenicline tartrate) 0.
    5mg and 1mg tablets in the United States due to excessive carcinogenic substances
    .

    Pfizer said in a statement that it took this action because it detected that the carcinogen nitrosamine (N-nitroso-varenicline) reached or exceeded the acceptable level set by the FDA
    .
    There are already alternative suppliers approved in the United States


    .


    Pfizer added that although long-term intake of nitrosamines may theoretically increase the risk of cancer in humans, there is no immediate risk for patients taking this drug
    .
    He also stated that the health benefits of quitting smoking outweigh the theoretical potential carcinogenic risk of nitrosamine impurities in varenicline


    .


    In June of this year, the US pharmaceutical giant stopped Chantix’s global sales and pointed out that the content of nitrosamines exceeded the “acceptable” daily intake


    In 2020, Chantix generated sales of US$919 million for Pfizer, a year-on-year decrease of approximately 17.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.